MESO Stock - Mesoblast Limited
Unlock GoAI Insights for MESO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $17.20M | $5.90M | $7.50M | $10.21M | $7.46M |
| Gross Profit | $12.07M | $-35,168,000 | $-47,421,000 | $-53,361,000 | $-78,275,000 |
| Gross Margin | 70.2% | -595.9% | -632.2% | -522.6% | -1049.8% |
| Operating Income | $-62,443,000 | $-84,147,000 | $-69,289,000 | $-80,574,000 | $-109,096,000 |
| Net Income | $-102,142,000 | $-87,956,000 | $-81,889,000 | $-91,347,000 | $-98,811,000 |
| Net Margin | -593.9% | -1490.3% | -1091.7% | -894.6% | -1325.3% |
| EPS | $-0.84 | $-0.89 | $-0.98 | $-1.30 | $-1.60 |
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Visit WebsiteEarnings History & Surprises
MESOEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 25, 2026 | — | — | — | — |
Q3 2025 | Sep 3, 2025 | $-0.20 | $-0.21 | -6.4% | ✗ MISS |
Q3 2025 | Sep 3, 2025 | $-0.20 | — | — | — |
Q2 2025 | Apr 30, 2025 | — | — | — | — |
Q1 2025 | Feb 26, 2025 | $-0.25 | $-0.02 | +91.6% | ✓ BEAT |
Q4 2024 | Oct 30, 2024 | $-0.31 | $-0.28 | +9.7% | ✓ BEAT |
Q3 2024 | Jul 4, 2024 | $-0.35 | $-0.26 | +25.7% | ✓ BEAT |
Q2 2024 | Jun 27, 2024 | — | $-0.26 | — | — |
Q1 2024 | Mar 25, 2024 | $-0.40 | $-0.34 | +15.0% | ✓ BEAT |
Q4 2023 | Dec 26, 2023 | $-0.13 | $-0.12 | +7.7% | ✓ BEAT |
Q3 2023 | Aug 30, 2023 | $-0.32 | $-0.28 | +12.5% | ✓ BEAT |
Q2 2023 | May 25, 2023 | $-0.36 | $-0.26 | +27.8% | ✓ BEAT |
Q1 2023 | Feb 27, 2023 | $-0.30 | $-0.34 | -13.3% | ✗ MISS |
Q4 2022 | Nov 22, 2022 | $-0.20 | $-0.24 | -20.0% | ✗ MISS |
Q3 2022 | Aug 30, 2022 | $-0.10 | $-0.34 | -240.0% | ✗ MISS |
Q2 2022 | May 31, 2022 | $-0.16 | $-0.32 | -100.0% | ✗ MISS |
Q1 2022 | Feb 24, 2022 | $-0.39 | $-0.40 | -3.7% | ✗ MISS |
Q4 2021 | Nov 23, 2021 | $-0.30 | $-0.34 | -13.3% | ✗ MISS |
Q3 2021 | Aug 31, 2021 | $-0.32 | $-0.34 | -6.3% | ✗ MISS |
Q2 2021 | Jun 2, 2021 | $-0.20 | $-0.44 | -120.0% | ✗ MISS |
Latest News
Frequently Asked Questions about MESO
What is MESO's current stock price?
What is the analyst price target for MESO?
What sector is Mesoblast Limited in?
What is MESO's market cap?
Does MESO pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to MESO for comparison